Head-To-Head Survey: Vivos Therapeutics (VVOS) versus Its Rivals

Vivos Therapeutics (NASDAQ:VVOS) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare Vivos Therapeutics to related companies based on the strength of its analyst recommendations, earnings, profitability, dividends, valuation, risk and institutional ownership.

Institutional & Insider Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Vivos Therapeutics has a beta of 6.37, indicating that its share price is 537% more volatile than the S&P 500. Comparatively, Vivos Therapeutics’ peers have a beta of 2.57, indicating that their average share price is 157% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Vivos Therapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
Vivos Therapeutics Competitors	4280	10550	18329	829	2.46

Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 2,888.26%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.29%. Given Vivos Therapeutics’ higher probable upside, equities analysts plainly believe Vivos Therapeutics is more favorable than its peers.

Profitability

This table compares Vivos Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Vivos Therapeutics Competitors	-304.51%	-178.77%	-22.17%

Valuation & Earnings

This table compares Vivos Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vivos Therapeutics	$20.90 million	-$21.17 million	-0.05
Vivos Therapeutics Competitors	$1.90 billion	$136.81 million	11.08

Vivos Therapeutics’ peers have higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Vivos Therapeutics peers beat Vivos Therapeutics on 10 of the 13 factors compared.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.